Exact Sciences EXAS
-
9 Rallying Biotech Stocks Being Snapped Up By Hedge Funds
By Kapitall : Interested in the growth prospects of the biotech industry? For a closer look at stocks of the biotech sector with positive market sentiment, we ran a screen. We began by screening the biotech industry for stocks currently rallying above their 20-day, 50-day, and 200-day moving ...
-
9 High-Growth Biotech Stocks Being Bought Up By Hedge Funds
By Kapitall : If you're interested in adding some growth to your portfolio, we ran a screen on the biotech industry keeping this idea in mind. We began by screening US-traded stocks of the biotech industry for those with high growth prospects, with 5-year projected EPS growth above 20%. We then ...
-
20 Biotech Stocks Being Bought Up By Hedge Funds
By Kapitall : The biotech industry is considered a growth industry with a very unique set of risks, mainly concerning the ability for research to turn into commercial success. For ideas on how to analyze stocks in the industry, we ran a screen. We screened the biotech industry for stocks seeing ...
-
Exact Sciences Could Be Exactly What Biotech Investors Need
… molecular diagnostics companies to watch at present is Exact Sciences ( EXAS ) - a small biotech company in pivotal studies for ..... Years To The Starting Line If things go to plan, Exact Sciences should be launching the Cologuard test about two …
-
EXACT Sciences ( EXAS ): Q4 EPS of -$0.18 misses by $0.01. Revenue of $1.04m (-28.6% Y/Y) in-line. (PR)
EXACT Sciences ( EXAS ): Q4 EPS of -$0.18 misses by $0.01 . Revenue of $1.04m (-28.6% Y/Y) in-line. ( PR ) Post your comment!
-
My Annual Top Ten Stock Picks For 2012: Part I
By Chris Katje : This article marks the fourth annual year of providing a top ten list on Seeking Alpha of stocks I believe will outperform the market. This year the picks are divided into three articles as the analysis is lengthier than before. I hope you enjoy the picks and can use the ...
-
Exact Sciences ([[ EXAS ]] -4.1%) dips after pricing its previously announced 3.12M share public offering at $8.00 per share, a 4.6% discount to yesterday's closing price.
Exact Sciences ( EXAS -4.1% ) dips after pricing its previously announced 3.12M share public offering at $8.00 per share, a 4.6% discount to yesterday's closing price. Post your comment!
-
Premarket gainers: [[PPHM]] +30%. [[FRO]] +29%. [[AMR]] +9%. [[LNKD]] +5%. [[EK]] +4%.Losers: [[PLX]] -20%. [[DRI]] -8%. [[CLWR]] -6%. [[NS]] -5%. [[MTL]] -5%. [[ EXAS ]] -5%. [[ALU]] -5%.
Premarket gainers: PPHM +30% . FRO +29% . AMR +9% . LNKD +5% . EK +4% . Losers: PLX -20% . DRI -8% . CLWR -6% . NS -5% . MTL -5% . EXAS -5% . ALU -5% . Post your comment!
-
Exact Sciences ( EXAS ) announces a secondary offering for a yet undisclosed amount of shares. Robert W. Baird is acting as sole book-running manager in the offering. Shares -6% AH.
Exact Sciences ( EXAS ) announces a secondary offering for a yet undisclosed amount of shares. Robert W. Baird is acting as sole book-running manager in the offering. Shares -6% AH. Post your comment!
-
Exact Sciences Setting The Standard For Early Cancer Detection
By VFC : Should the impressive results from Exact Sciences Corporation's ( EXAS ) colon and colorectal cancer detection diagnostic test continue through ongoing studies, this company could be positioned to …